End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.41 MXN | -1.90% | +4.20% | -1.82% |
04-24 | Transcript : ALPEK, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 24, 2024 | |
04-23 | ALPEK, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- With a P/E ratio at 13.79 for the current year and 8.08 for next year, earnings multiples are highly attractive compared with competitors.
- The stock, which is currently worth 2024 to 0.38 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.82% | 1.52B | B+ | ||
+22.35% | 5.62B | C | ||
-11.57% | 4.38B | C- | ||
-1.44% | 3.63B | C | ||
-2.38% | 2.05B | - | - | |
-6.46% | 931M | - | ||
-18.10% | 880M | - | D+ | |
-3.17% | 601M | - | - | |
-27.91% | 437M | - | ||
-17.44% | 385M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALPEK A Stock
- Ratings ALPEK, S.A.B. de C.V.